Cargando…

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis

Detalles Bibliográficos
Autores principales:	Yoon, Seoyoung, Shin, Cheolmin, Jeon, Sangwon, Han, Changsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616752/ http://dx.doi.org/10.1093/ijnp/pyw043.156

Ejemplares similares

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

PS227. Psychometric Properties of the Korean Version of the Clinically Useful Depression Outcome Scale (CUDOS) in Psychiatric Outpatients
por: Han, Changsu, et al.
Publicado: (2016)

Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data
por: Shin, Cheolmin, et al.
Publicado: (2019)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

PS90. Differences in hypochondriasis between Korean and American outpatients with major depressive disorder
por: Kim, Jiyeon, et al.
Publicado: (2016)

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
por: Carpenter, Joanne S, et al.
Publicado: (2022)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA
por: Kim, Seoyoung, et al.
Publicado: (2018)

PS238. Altered balance between monoamine metabolites in human cerebrospinal fluid with major depressive disorder.
por: Yoon, Hyung Shin, et al.
Publicado: (2016)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

PS281. Lifetime suicidal ideation and attempt in community adults with full major depressive disorder versus only sustained depressed mood
por: Yoo, Hye Jin, et al.
Publicado: (2016)

Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014
por: Shin, Cheolmin, et al.
Publicado: (2017)

PS232. Influence of alexithymia on the prognosis of patients with major depression treated using pharmacotherapy.
por: Mantani, Tomoyuki, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

PS96. The change of prescribing patterns for inpatients of major depressive disorder
por: Kim, Hyeri, et al.
Publicado: (2016)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
por: Maoz, H.
Publicado: (2023)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

PS46. Distinct and shared morphometric biomarkers of depressed individuals with bipolar disorder and major depressive disorder
por: Matsuo, Koji, et al.
Publicado: (2016)

PS195. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder
por: Ogawa, Shintaro, et al.
Publicado: (2016)

PS163. Serotonin Transporter Polymorphism in Severe Major Depressive Disorder in Indonesia
por: Arlisa, Wulandari, et al.
Publicado: (2016)

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
por: Shin, Cheolmin, et al.
Publicado: (2020)

PS129. Low TNFAIP3 was normalized with antidepressant in patients with major depressive disorder
por: Hung, Yi-Yung
Publicado: (2016)

PS50. The serum oxytocin levels among major depressive and bipolar II disorder
por: Lien, Yueh-Ju, et al.
Publicado: (2016)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9j6ohcnc7nm64dqr9ria6dh4fh